bpc-157 vs tb-500
bpc-157 (A-tier) vs tb-500 (A-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.
bpc-157 — tier A
the contested repair peptide. strong animal data, thin human trials, huge community gravity.
the contested repair peptide. 200+ rat studies with consistent tissue-repair signals. zero published controlled human RCTs in tendon or injury recovery.
200+ rodent · 0 RCTs · half-life short (minutes IV) · healing
tb-500 — tier A
names a 7-amino-acid fragment of thymosin beta-4, but the vial you buy is a coin toss: fragment, full-length protein, or mislabeled. the COA mass is the only thing that knows.
the name means a 7-amino-acid fragment of thymosin beta-4, but vendor vials routinely contain the full 43-amino-acid protein instead, and the label does not tell you which. the molecule is real and the human proof is not.
banned USEF 2014 · half-life ~0.5 to 2 hours (human phase-1 PK, PMID 34346165; dose-dependent), same as full thymosin beta-4 when that is what the vial holds; the bare heptapeptide clears faster · healing
at a glance
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.